Global Veterinary Drugs Market Size By Type (Treatment Drugs, Vaccines), By Application (Chickens, Swine), By Region, And Segment Forecasts, 2023 to 2032

The Global Veterinary Drugs Market was valued at USD 42.7 billion in 2023 and is projected to reach USD 73.6 billion by 2031, expanding at a CAGR of 6.9% during the forecast period of 2023–2031. The market’s robust growth is primarily fueled by increasing pet ownership, growing livestock production for food supply, and the rising incidence of zoonotic and chronic diseases among animals. Continuous innovation in veterinary pharmaceuticals and an expanding demand for preventive healthcare for companion and farm animals are further driving the adoption of veterinary drugs globally.

Drivers:

1. Rising Pet Ownership and Animal Humanization:

Growing attachment to pets and increased spending on their health has fueled the demand for a wide range of veterinary drugs, especially in developed markets. Owners are increasingly investing in advanced treatments, preventive care, and wellness products for companion animals.

2. Expansion of Livestock Industry:

With the global rise in demand for animal-derived food products, livestock farming is on the rise. This expansion necessitates the use of veterinary drugs for disease prevention and productivity enhancement in cattle, poultry, and swine.

3. Increasing Incidence of Zoonotic Diseases:

Emerging zoonotic outbreaks and cross-species infections like avian flu and swine fever have prompted governments and veterinary professionals to implement widespread drug-based disease control programs, accelerating the need for antibiotics, antiparasitics, and vaccines.

Restraints:

1. Stringent Regulatory Framework:

Veterinary drugs undergo rigorous approval and compliance standards across various regions, which can hinder product launches and elongate time-to-market for manufacturers.

2. Growing Concern over Antimicrobial Resistance (AMR):

Excessive or improper use of antibiotics in animals contributes to antimicrobial resistance, prompting regulatory authorities to enforce usage restrictions, thereby potentially limiting market growth.

Opportunity:

1. Growth in Preventive Healthcare and Specialty Drugs:

The market is seeing a rise in demand for vaccines, pain management drugs, and nutritional supplements, especially for aging pets and high-value livestock. This shift toward preventive healthcare is opening lucrative avenues for manufacturers.

2. Technological Advancements in Veterinary Therapeutics:

The integration of nanotechnology, biologics, and advanced drug delivery systems is revolutionizing the efficacy of veterinary treatments, offering players opportunities to develop next-generation therapeutics.

Market by System Type Insights:

By drug type, the Anti-infectives segment accounted for the largest market share in 2023, owing to its widespread use in disease treatment and prevention in both companion and livestock animals. However, the Parasiticides segment is projected to witness the highest CAGR during the forecast period due to growing incidences of parasitic infections and the availability of broad-spectrum parasiticides.

Market by End-use Insights:

By end-use, the Livestock segment dominated the market in 2023, contributing to over 55% of the global revenue. This is attributed to the high demand for meat, milk, and eggs globally. Meanwhile, the Companion animal segment is anticipated to witness faster growth, driven by urbanization, nuclear families, and increased spending on pet health.

Market by Regional Insights:

Regionally, North America led the global veterinary drugs market in 2023, driven by high pet adoption rates, robust animal healthcare infrastructure, and proactive veterinary drug approvals. Asia-Pacific is expected to be the fastest-growing region during the forecast period due to its expanding livestock base, rising pet ownership, and improving veterinary healthcare facilities in countries like China and India.

Competitive Scenario:

Key players operating in the Global Veterinary Drugs Market include Zoetis Inc., Merck Animal Health, Elanco Animal Health, Boehringer Ingelheim Vetmedica, Ceva Santé Animale, Virbac, Vetoquinol, Bayer AG, Dechra Pharmaceuticals, and Phibro Animal Health Corporation. These companies are focusing on R&D investments, global expansion, and product pipeline diversification to strengthen their market share.

Noteworthy developments include:

In 2023, Zoetis launched a new class of monoclonal antibody therapy for chronic pain management in dogs.

In 2024, Merck Animal Health expanded its manufacturing facility to meet the growing demand for livestock vaccines in Asia.

In 2025, Elanco introduced an oral parasiticide for cats with improved palatability and extended protection.

Scope of Work – Global Veterinary Drugs Market

Key Market Developments:

2023: Zoetis introduced Simparica Trio® for flea, tick, and heartworm prevention in dogs, combining three active ingredients in a single chewable tablet.

2024: Boehringer Ingelheim launched a long-acting injectable antibiotic for cattle that reduces the frequency of treatment.

2025: Ceva Santé Animale acquired a regional veterinary biotech firm to strengthen its parasiticide portfolio in Latin America.

FAQs:

1) What is the current market size of the Global Veterinary Drugs Market?

The Global Veterinary Drugs Market was valued at USD 42.7 billion in 2023.

2) What is the major growth driver of the Global Veterinary Drugs Market?

The primary growth drivers include rising pet ownership, livestock expansion, and increasing zoonotic diseases.

3) Which is the largest region during the forecast period in the Global Veterinary Drugs Market?

North America held the largest share in 2023, while Asia-Pacific is projected to witness the highest growth rate.

4) Which segment accounted for the largest market share in the Global Veterinary Drugs Market?

The Livestock segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Veterinary Drugs Market?

Major players include Zoetis, Merck Animal Health, Elanco, Boehringer Ingelheim, and Ceva Santé Animale.